<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04620967</url>
  </required_header>
  <id_info>
    <org_study_id>2020-001158-23</org_study_id>
    <secondary_id>H-20022359</secondary_id>
    <nct_id>NCT04620967</nct_id>
  </id_info>
  <brief_title>Fast-Acting Insulin Aspart and Insulin Pump Settings</brief_title>
  <official_title>Fast-Acting Insulin Aspart and Insulin Pump Settings: THE FAST PUMP SETTING STUDY</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kirsten Nørgaard</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Steno Diabetes Center Copenhagen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To clarify the role of fast-acting insulin aspart (Fiasp) in insulin pump-treated type 1&#xD;
      diabetes more research is needed.&#xD;
&#xD;
      The aim of this study is twofold:&#xD;
&#xD;
        1. to compare the effects of Fiasp and Iasp in adults with type 1 diabetes who are using&#xD;
           insulin pump and CGM and who are attending a diabetes out-patient clinic with extensive&#xD;
           expertise in insulin pump and CGM therapy.&#xD;
&#xD;
        2. to determine differences in insulin pump settings when insulin pumps are optimally&#xD;
           adjusted to each of the two insulin types.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>A randomized, double-blind, cross-over study with two 16-week intervention periods separated by a 3-week washout period comparing Fiasp with Iasp in adults with type 1 diabetes treated with insulin pump and CGM.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Group allocation is concealed to participants as well as investigators until all participants have completed the study. The allocation for a participant may be revealed in a medical emergency if knowledge about the treatment allocation would influence the treatment of the person.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Time in range</measure>
    <time_frame>Last two weeks of the 16-week interventions</time_frame>
    <description>Difference in time spent with glucose values in the range 3.9-10.0 mmol/l between Fiasp and Iasp treatment assessed by continuous glucose monitoring</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean glucose</measure>
    <time_frame>Last two weeks of the 16-week interventions</time_frame>
    <description>Difference in mean glucose between Fiasp and Iasp treatment assessed by continuous glucose monitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coefficient of variation</measure>
    <time_frame>Last two weeks of the 16-week interventions</time_frame>
    <description>Difference in coefficient of variation between Fiasp and Iasp treatment assessed by continuous glucose monitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time below range level 1</measure>
    <time_frame>Last two weeks of the 16-week interventions</time_frame>
    <description>Difference in time spent with glucose values below 3.9 mmol/l between Fiasp and Iasp treatment assessed by continuous glucose monitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time below range level 2</measure>
    <time_frame>Last two weeks of the 16-week interventions</time_frame>
    <description>Difference in time spent with glucose values below 3.0 mmol/l between Fiasp and Iasp treatment assessed by continuous glucose monitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time above range level 1</measure>
    <time_frame>Last two weeks of the 16-week interventions</time_frame>
    <description>Difference in time spent with glucose values above 10.0 mmol/l between Fiasp and Iasp treatment assessed by continuous glucose monitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time above range level 2</measure>
    <time_frame>Last two weeks of the 16-week interventions</time_frame>
    <description>Difference in time spent with glucose values above 13.9 mmol/l between Fiasp and Iasp treatment assessed by continuous glucose monitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fructosamine</measure>
    <time_frame>16 weeks</time_frame>
    <description>Difference in change in fructosamine between Fiasp and Iasp treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total daily insulin dose</measure>
    <time_frame>Last two weeks of the 16-week interventions</time_frame>
    <description>Difference between Fiasp and Iasp treatment in total daily insulin dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total daily basal insulin dose</measure>
    <time_frame>Last two weeks of the 16-week interventions</time_frame>
    <description>Difference between Fiasp and Iasp treatment in total daily basal insulin dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total daily bolus insulin dose</measure>
    <time_frame>Last two weeks of the 16-week interventions</time_frame>
    <description>Difference between Fiasp and Iasp treatment in total daily bolus insulin dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe hypoglycemia</measure>
    <time_frame>16 weeks</time_frame>
    <description>Difference between Fiasp and Iasp treatment in number of severe hypoglycemia events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ketoacidosis</measure>
    <time_frame>16 weeks</time_frame>
    <description>Difference between Fiasp and Iasp treatment in number of ketoacidosis events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>Iasp-Fiasp</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>First period: Insulin pump with Iasp Second period: Insulin pump with Fiasp</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fiasp-Iasp</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>First period: Insulin pump with Fiasp Second period: Insulin pump with Iasp</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin aspart</intervention_name>
    <description>Insulin aspart (Iasp) in insulin pump</description>
    <arm_group_label>Fiasp-Iasp</arm_group_label>
    <arm_group_label>Iasp-Fiasp</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fast-acting insulin aspart</intervention_name>
    <description>Fast-acting insulin aspart (Fiasp) in insulin pump</description>
    <arm_group_label>Fiasp-Iasp</arm_group_label>
    <arm_group_label>Iasp-Fiasp</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Type 1 diabetes for ≥ 5 years&#xD;
&#xD;
          -  HbA1c 53-75 mmol/mol (7.0-9.0%)&#xD;
&#xD;
          -  Insulin pump treatment for ≥ 6 months (all insulin pump makes except hybrid&#xD;
             closed-loop systems are eligible for inclusion)&#xD;
&#xD;
          -  CGM use for ≥ 6 months (all CGM makes are eligible for inclusion)&#xD;
&#xD;
          -  Carbohydrate counting for all snacks and meals&#xD;
&#xD;
          -  Use of the insulin pump bolus calculator for all meals and snacks&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Breast-feeding, pregnant, planning to become pregnant or of child-bearing potential&#xD;
             and not using adequate contraceptive methods&#xD;
&#xD;
          -  Gastroparesis (clinical assessment)&#xD;
&#xD;
          -  Shift work&#xD;
&#xD;
          -  Changing insulin needs throughout the menstrual cycle that requires different basal&#xD;
             rate patterns&#xD;
&#xD;
          -  Use of a hybrid closed-loop system&#xD;
&#xD;
          -  Use of flash glucose monitoring&#xD;
&#xD;
          -  Use of anti-diabetic medicine (other than insulin), corticosteroids or other drugs&#xD;
             affecting glucose metabolism during the study period or within 30 days prior to study&#xD;
             start&#xD;
&#xD;
          -  Chronic paracetamol use&#xD;
&#xD;
          -  Alcohol or drug abuse&#xD;
&#xD;
          -  Severe cardiac disease or retinopathy contraindicating HbA1c below 53 mmol/mol&#xD;
&#xD;
          -  Impaired renal function (eGFR&lt; 60 ml/min/1.73 m2)&#xD;
&#xD;
          -  History of local skin reactions to Fiasp and/or Iasp&#xD;
&#xD;
          -  Other concomitant medical or psychological condition that according to the&#xD;
             investigator's assessment makes the patient unsuitable for study participation&#xD;
&#xD;
          -  Lack of compliance with key study procedures at the discretion of the investigator&#xD;
&#xD;
          -  Unacceptable adverse events at the discretion of the investigator&#xD;
&#xD;
          -  Less than 40 weeks guarantee remaining on insulin pump&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kirsten Nørgaard, MD DMSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Steno Diabetes Center Copenhagen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Signe Schmidt, MD PhD</last_name>
    <phone>+45 51174785</phone>
    <email>signe.schmidt@regionh.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Steno Diabetes Center Copenhagen</name>
      <address>
        <city>Gentofte</city>
        <zip>2820</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Signe Schmidt, MD PhD</last_name>
      <phone>+45 51174785</phone>
      <email>signe.schmidt@regionh.dk</email>
    </contact>
    <investigator>
      <last_name>Ajenthen Ranjan, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hanne-Charlotte Andersen, RN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Signe Schmidt, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>November 3, 2020</study_first_submitted>
  <study_first_submitted_qc>November 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2020</study_first_posted>
  <last_update_submitted>February 12, 2021</last_update_submitted>
  <last_update_submitted_qc>February 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Steno Diabetes Center Copenhagen</investigator_affiliation>
    <investigator_full_name>Kirsten Nørgaard</investigator_full_name>
    <investigator_title>Senior Consultant</investigator_title>
  </responsible_party>
  <keyword>Insulin pump</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin Aspart</mesh_term>
    <mesh_term>Insulin, Long-Acting</mesh_term>
    <mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

